Raymond James Financial Services Advisors, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 67,401 shares of RXRX stock, worth $488,657. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,401
Previous 89,980
25.09%
Holding current value
$488,657
Previous $674,000
34.12%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RXRX
# of Institutions
298Shares Held
241MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$235 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$180 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$176 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$125 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$112 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.31B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...